Chen Xiaoping, Yang Wenying
Department of Endocrinology China-Japan Friendship Hospital Beijing China.
J Diabetes Investig. 2014 Sep;5(5):478-81. doi: 10.1111/jdi.12254. Epub 2014 Jul 25.
Epidemiology is now well recognized as the foundation of public health. The Da Qing study in 1986 was the first milestone study to show that lifestyle intervention can prevent or delay the onset of diabetes. The lead investigator of that study, Professor Xiaoren Pan, is regarded as the forerunner epidemiologist for diabetes in China and even in Asia. In 2006, study participants were followed up to assess the long-term effects of the interventions after 20 years. As compared with the control group, those in the combined lifestyle intervention group had a 51% lower incidence of diabetes during the active intervention period and a 43% lower incidence over the 20-year period, adjusted by age. Recently, the National Diabetes Prevalence Survey in China was carried out from 2007 to 2008. The data from that study showed that the prevalence of diabetes in Chinese adults was 9.7%, and the increased rate of diabetes prevalence in China exceeded the International Diabetes Federation estimation. Very recently, we have reported that acarbose is a viable choice for initial therapy in Chinese patients newly diagnosed with type 2 diabetes who have a lower body mass index and exaggerated postprandial glucose excursion compared with Caucasian patients. We are expecting more contributions from epidemiology to the study of diabetes.
流行病学如今已被公认为公共卫生的基础。1986年的大庆研究是首个表明生活方式干预可预防或延缓糖尿病发病的里程碑式研究。该研究的首席研究员潘孝仁教授被视为中国乃至亚洲糖尿病流行病学的先驱。2006年,对研究参与者进行了随访,以评估20年后干预措施的长期效果。与对照组相比,综合生活方式干预组在积极干预期间糖尿病发病率降低了51%,在20年期间经年龄调整后发病率降低了43%。最近,中国在2007年至2008年开展了全国糖尿病患病率调查。该研究数据显示,中国成年人糖尿病患病率为9.7%,中国糖尿病患病率的上升速度超过了国际糖尿病联盟的估计。就在最近,我们报告称,与高加索患者相比,阿卡波糖是中国新诊断的2型糖尿病患者初始治疗的一个可行选择,这些患者体重指数较低且餐后血糖波动较大。我们期待流行病学对糖尿病研究做出更多贡献。